Final results of a phase Ib/IIa study of phenoxodiol in hormone-refractory prostate cancer.

被引：0
|
作者：
Davies, R
Tulloch, A
Frydenberg, M
Kelly, G
机构：
[1] Sir Charles Gairdiner Hosp, Perth, WA, Australia
[2] St John God Hosp, Perth, WA, Australia
[3] Monash Med Ctr, Melbourne, Vic, Australia
[4] Marshall Edwards Inc, Sydney, NSW, Australia
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9123S / 9123S
页数：1
相关论文
共 50 条
  • [21] Metastasizing hormone-refractory prostate cancer. Chemotherapy and new treatment approaches
    Wierecky, J.
    Bokemeyer, C.
    ONKOLOGE, 2007, 13 (08): : 726 - +
  • [22] Phase II trial of weekly docetaxel and oral capecitabine in metastatic hormone-refractory prostate cancer.
    Marur, S.
    Heilbrun, L.
    Kucuk, O.
    Cher, M. L.
    Forman, J.
    Heath, E.
    Vaishampayan, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 250S - 250S
  • [23] Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study
    J Carles
    A Font
    B Mellado
    M Domenech
    E Gallardo
    J L González-Larriba
    G Catalan
    J Alfaro
    A Gonzalez del Alba
    M Nogué
    P Lianes
    J M Tello
    British Journal of Cancer, 2007, 97 : 1206 - 1210
  • [24] Chemotherapy of the hormone-refractory prostate cancer
    Heine, K
    Wolff, JM
    AKTUELLE UROLOGIE, 2004, 35 (03) : 209 - 214
  • [25] Management of hormone-refractory prostate cancer
    Dogliotti, L
    Mosca, A
    TUMORI, 2003, : S147 - S149
  • [26] Taxanes in hormone-refractory prostate cancer
    Kang, MH
    Figg, WD
    Dahut, W
    CANCER PRACTICE, 1999, 7 (05) : 270 - 272
  • [27] Therapy of hormone-refractory prostate cancer
    Heidenreich, A
    UROLOGE, 2005, 44 (12): : 1481 - 1494
  • [28] A phase II trial of irinotecan in hormone-refractory prostate cancer
    Reese, DM
    Tchekmedyian, S
    Chapman, Y
    Prager, D
    Rosen, PJ
    INVESTIGATIONAL NEW DRUGS, 1999, 16 (04) : 353 - 359
  • [29] Satraplatin for hormone-refractory prostate cancer
    Kerr, Cathel
    LANCET ONCOLOGY, 2007, 8 (04): : 290 - 290
  • [30] A phase II trial of irinotecan in hormone-refractory prostate cancer
    David M. Reese
    Simon Tchekmedyian
    Yvonne Chapman
    Diane Prager
    Peter J. Rosen
    Investigational New Drugs, 1998, 16 : 353 - 359
12345